Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Delcath Systems, Inc. before investing.

In this article, we go over a few key elements for understanding Delcath Systems, Inc.’s stock price such as:

• Delcath Systems, Inc.’s current stock price and volume
• Why Delcath Systems, Inc.’s stock price changed recently
• Upgrades and downgrades for DCTH from analysts
• DCTH’s stock price momentum as measured by its relative strength

About Delcath Systems, Inc. (DCTH)

Before we jump into Delcath Systems, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.

Want to learn more about Delcath Systems, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Delcath Systems, Inc..

Delcath Systems, Inc.’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, Delcath Systems, Inc.’s stock price was $9.700.

Delcath Systems, Inc. is up 0.62% from its previous closing price of $9.640.

During the last market session, Delcath Systems, Inc.’s stock traded between $9.554 and $9.950. Currently, there are approximately 36.38 million shares outstanding for Delcath Systems, Inc..

Delcath Systems, Inc.’s price-earnings (P/E) ratio is currently at 277.1, which is high compared to the Health Care Equipment & Supplies industry median of 33.3. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Delcath Systems, Inc. Stock Price History

Delcath Systems, Inc.’s (DCTH) price is currently down 1.32% so far this month.

During the month of November, Delcath Systems, Inc.’s stock price has reached a high of $9.950 and a low of $8.120.

Over the last year, Delcath Systems, Inc. has hit prices as high as $18.230 and as low as $8.120. Year to date, Delcath Systems, Inc.’s stock is down 19.44%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Delcath Systems, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there were 0 analysts who downgraded Delcath Systems, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Delcath Systems, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Delcath Systems, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Delcath Systems, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Delcath Systems, Inc. (DCTH) by visiting AAII Stock Evaluator.

Relative Price Strength of Delcath Systems, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, Delcath Systems, Inc. has a weighted four-quarter relative price strength of -4.42%, which translates to a Momentum Score of 44 and is considered to be Average.

Want to learn more about how Delcath Systems, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Delcath Systems, Inc. Stock Price: Bottom Line

As of November 28, 2025, Delcath Systems, Inc.’s stock price is $9.700, which is up 0.62% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Delcath Systems, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.